Scientific deep-dive
Tirzepatide Constipation: Causes, FDA-Label Rates & Evidence-Based Relief Protocol
Tirzepatide constipation appears in 11-17% on Zepbound (label pool) vs 5% placebo; 6-7% on Mounjaro. Dual GIP+GLP-1 mechanism delays gastric emptying. Relief: fiber about 14 g per 1,000 kcal, fluids 2.5-3L, magnesium citrate. Ileus red flags covered.
Constipation is one of the four most-common GI side effects on tirzepatide — the active ingredient in both Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). The Zepbound FDA label Section 6.1, pooling SURMOUNT-1 and SURMOUNT-2, reports constipation in 17% of patients on 5 mg, 14% on 10 mg and 11% on 15 mg vs. 5% on placebo[2][3]. The mechanism stacks two slow-down signals: GLP-1 receptor activation plus glucose-dependent insulinotropic polypeptide (GIP) receptor activation, both of which delay gastric emptying and slow lower-GI transit[8][9]. This guide covers what SURMOUNT-1, SURMOUNT-4, and SURMOUNT-OSA actually reported, how tirzepatide compares head-to-head with semaglutide, the evidence-based relief protocol, and the FDA-label red flags that mean stop self-managing and call your prescriber.
The honest short answer
Tirzepatide-related constipation is real, common, and almost always manageable without stopping the drug. The Zepbound FDA label Section 6.1 lists constipation at 17% on 5 mg, 14% on 10 mg and 11% on 15 mg vs. 5% on placebo in its pool of SURMOUNT-1 and SURMOUNT-2; the Mounjaro label reports lower rates of 6–7% across doses (7% at 15 mg) vs. 1% on placebo in its pool of placebo-controlled type 2 diabetes trials[1][2][3]. Most patients respond to first-line conservative measures: deliberate fiber, adequate fluids, daily movement, and (if needed) a 200–400 mg magnesium citrate at bedtime. Stop self-managing and call your prescriber if you go 5+ days without a bowel movement, if you have progressive abdominal distension, or if vomiting joins the picture.
What SURMOUNT-1, SURMOUNT-4, and SURMOUNT-OSA actually measured
The Zepbound FDA-label constipation rates come from the SURMOUNT obesity-trial program. Jastreboff and colleagues’ SURMOUNT-1 publication in the New England Journal of Medicine (2022) is the 72-week pivotal trial in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) plus a weight-related comorbidity[3]. In the Zepbound FDA label’s adverse-reactions table, which pools SURMOUNT-1 with SURMOUNT-2, constipation was reported in 17% of the 5 mg arm, 14% of the 10 mg arm, 11% of the 15 mg arm, and 5% of placebo; the rate was highest at the lowest dose, not the highest[2][3].
SURMOUNT-4 (Aronne 2024 JAMA) tested the maintenance question: what happens to GI tolerability if a patient stops vs. continues tirzepatide after the first ~9 months? Patients who completed a 36-week open-label tirzepatide lead-in were randomized to continue the maintenance dose (10 or 15 mg) or switch to placebo for an additional 52 weeks[4]. Constipation rates in the continued-tirzepatide arm remained in the high single-digit-percent range over the maintenance year, vs. lower rates in the placebo-switch arm — consistent with the motility effect being present as long as the drug is on board.
SURMOUNT-OSA (Malhotra 2024 NEJM) extended the adverse-event picture into a different population: adults with moderate-to-severe obstructive sleep apnea and obesity, treated for 52 weeks with tirzepatide titrated to a maximum tolerated dose of 10 or 15 mg[5]. Constipation appeared in the publication’s adverse-event table at single-digit-percent rates similar to SURMOUNT-1, confirming the rate is not an artifact of any one SURMOUNT population.
Mechanism — why tirzepatide’s dual agonism slows transit
Tirzepatide is a once-weekly synthetic peptide that activates two incretin receptors: the GLP-1 receptor (the same target as semaglutide, dulaglutide, and liraglutide) and the GIP receptor. Both receptors are expressed on enteric neurons, gastric smooth muscle, and the central appetite circuitry that controls hunger and satiety. Activation of either receptor slows gastric emptying; activation of both stacks the effect.
Urva and colleagues’ 2020 phase-1 PK study in Diabetes, Obesity and Metabolism measured tirzepatide’s gastric-emptying effect directly using acetaminophen-absorption pharmacokinetics[8]. The headline finding: tirzepatide produced a transient, dose-dependent delay in gastric emptying that on the first dose was comparable in magnitude to long-acting GLP-1 receptor agonists, with tachyphylaxis (waning of the gastric-emptying delay) developing over subsequent weeks — though the appetite and weight-loss effects persist long after the gastric-emptying signal has attenuated. Marathe and colleagues’ 2013 Peptides review summarized the broader GLP-1 mechanism: native GLP-1 and pharmacologic GLP-1 receptor agonists delay gastric emptying in a dose-dependent fashion, and this deceleration extends to the small intestine and colon[9].
Three additional factors stack on top of the direct motility effect:
- Lower food volume — tirzepatide’s appetite suppression is more profound than semaglutide’s in head-to-head trials (see tirzepatide vs. semaglutide head-to-head). Eating less means less fiber and less stool bulk. A 1,200-calorie day on tirzepatide without deliberate fiber planning can easily fall short of the recommended 14 g of fiber per 1,000 kcal, which works out to about 17 g at 1,200 kcal[10].
- Lower fluid intake — satiety on a GLP-1/GIP extends to thirst for many patients. The drink-with-meals prompt is weaker once you’re eating smaller portions.
- Concurrent antiemetics — if you’re using ondansetron (Zofran) for nausea during titration, that drug itself causes constipation, and the two effects stack. See our tirzepatide diarrhea management guide for the related GI-tolerance trade-off.
Practical relief protocol — fiber, fluids, magnesium, movement
The first-line relief protocol is conservative, well-supported, has no drug interactions, and is what most gastroenterologists recommend before any laxative.
Fiber: about 14 g per 1,000 kcal
Anderson and colleagues’ 2009 Nutrition Reviews synthesis concluded that higher fiber intake benefits several gastrointestinal disorders, constipation among them, put the recommended intake at 14 g per 1,000 kcal, and noted that average US intake is less than half of that[10]. On a 1,200–1,500 calorie tirzepatide day that works out to about 17–21g of fiber, and getting there requires deliberate planning — you cannot get there by accident on a typical Western reduced-calorie diet.
- Psyllium husk (Metamucil) — 1 tablespoon (~5g soluble fiber) in a full 8 oz glass of water, 1–3 times daily. The water is non-negotiable; psyllium without enough fluid can worsen constipation.
- Ground flaxseed — 1–2 tablespoons in yogurt, oatmeal, or a smoothie. ~3g fiber per tablespoon plus omega-3s.
- Chia seeds — 1–2 tablespoons, ideally hydrated for 10 minutes in liquid before eating. ~5g fiber per tablespoon.
- High-fiber whole foods — raspberries (8g per cup), pears with skin (5–6g each), avocado (10g each), lentils (15g per cup cooked), black beans (15g per cup), bran cereal (10g+ per serving).
Use our GLP-1 fiber calculator to plan a day that actually hits about 14 g per 1,000 kcal; without planning, most tirzepatide patients land between 8–12g.
Hydration 2.5–3L/day
Fiber without enough fluid is a worse outcome than no fiber. Insoluble fiber needs water to soften stool; soluble fiber needs water to form the gel that lubricates transit. The standard recommendation for an adult on a tirzepatide titration is 2.5–3 liters of non-caffeinated fluid per day — this is also the volume that protects against the FDA-label acute kidney injury risk flagged in Mounjaro Section 5.3 and Zepbound Section 5[1][2].
Magnesium citrate 200–400 mg at bedtime
Magnesium acts as an osmotic laxative in the colon — it pulls water into the bowel lumen, softening stool and accelerating transit. Mori and colleagues’ 2019 randomized double-blind placebo-controlled trial in the Journal of Neurogastroenterology and Motility demonstrated that oral magnesium oxide improved both stool frequency and consistency in chronic constipation patients vs. placebo over 28 days[11]. Magnesium citrate is the better-absorbed form for daily use; magnesium oxide is the form studied in the Mori RCT.
- Starting dose — 200 mg magnesium citrate at bedtime. Titrate up to 400 mg if needed and tolerated.
- Side effects — loose stools or diarrhea if you overshoot. Drop the dose if this happens.
- Contraindications — chronic kidney disease (CKD stage 3+), since impaired kidneys cannot excrete excess magnesium and can develop hypermagnesemia. Confirm with your prescriber if you have any renal impairment.
Polyethylene glycol 3350 (MiraLAX)
PEG 3350 is the over-the-counter osmotic laxative most gastroenterologists recommend for adult constipation. It’s non-absorbed, has minimal side effects, and is safe for long-term use. Dose: 17g (one capful) in 8 oz of fluid once daily; can be increased to twice daily if needed.
Walking, gentle movement, and dose stability
Physical activity stimulates colonic motility. A 20–30 minute walk after a meal is one of the highest-leverage, zero-side-effect interventions for sluggish bowel transit. Morning walks are particularly effective because the gastrocolic reflex (the colon waking up after the first meal of the day) is the strongest intrinsic peristaltic signal you have.
Dose stability also matters. SURMOUNT-1, SURMOUNT-4, and the manufacturer’s prescribing recommendations support pausing dose escalation if GI tolerability is poor — staying at 5 mg or 7.5 mg for an extra month rather than escalating on schedule is a reasonable strategy that gives the gut time to adapt before the next step up[3][4].
When to call your prescriber (red flags)
Both the Mounjaro and Zepbound FDA labels have been updated to acknowledge ileus — the functional shutdown of normal bowel peristalsis — as a postmarketing adverse reaction in the GLP-1/GIP class[1][2]. Ileus can mimic ordinary tirzepatide constipation in its early presentation but progresses to a medical emergency. The distinguishing features:
- No bowel movement for 5+ days AND no passage of gas (obstipation is the cardinal sign — more concerning than just hard or infrequent stool).
- Progressive abdominal distension — visibly swollen abdomen that is firm to the touch.
- Severe abdominal pain, especially crampy or colicky pain in waves.
- Vomiting, particularly vomiting of bile (green or yellow) or feculent (foul-smelling, dark) material.
- Inability to keep down fluids — the combination of obstipation plus emesis can drive you into the dehydration zone that the FDA label warns can cause acute kidney injury.
Any combination of these symptoms warrants urgent evaluation — call your prescriber immediately, or go to an emergency department if you cannot reach them quickly. Bring your tirzepatide pen or the label so the treating team knows you’re on a dual GIP/GLP-1 agonist. Ileus and bowel obstruction can require nasogastric decompression, IV fluids, and in severe cases surgical intervention.
Pancreatitis (Mounjaro label Section 5.2, Zepbound Section 5.2) is another rare but serious consideration that overlaps with severe GI symptoms[1][2]. Severe persistent abdominal pain that radiates to the back, with or without vomiting, warrants prompt evaluation regardless of whether constipation is the dominant symptom. The Zepbound label Section 5.7 also flags pulmonary aspiration risk during anesthesia in patients with retained gastric contents — another reason to disclose tirzepatide use ahead of any planned procedure.
How tirzepatide compares with semaglutide on constipation
Wilding and colleagues’ STEP-1 publication in the New England Journal of Medicine (2021) is the closest semaglutide comparator — same trial design (placebo-controlled, ~68–72 weeks, adults with obesity) and same primary GI adverse-event reporting methodology[6]. The Wegovy label, pooling its placebo-controlled weight-management trials including STEP-1, reports constipation in 24% on semaglutide 2.4 mg vs. 11% on placebo[12]. Side-by-side with the Zepbound label’s 11% constipation rate on tirzepatide 15 mg (17% at 5 mg), the head-to-head picture is somewhat counterintuitive: even though tirzepatide’s dual GIP + GLP-1 mechanism produces more gastric-emptying delay on first dose, the trial-reported cumulative-constipation rates on weight-loss doses are lower for tirzepatide than for semaglutide 2.4 mg[2][12].
Two caveats. First, the trials enrolled different patient populations and used different definitions of bothersome constipation, so direct rate-vs-rate comparisons need a grain of salt — the only fully head-to-head safety publication is SURMOUNT-5 (covered in our tirzepatide vs. semaglutide head-to-head article). Second, tirzepatide’s diarrhea rate is higher than semaglutide’s, suggesting some patients who would have been constipated on a GLP-1 mono-agonist are instead pushed into diarrhea-predominant GI tolerability by the GIP component — the net GI burden is comparable across the two drugs, just distributed differently along the constipation/diarrhea spectrum.
Magnitude comparison
Constipation reporting rates in the FDA-label placebo-controlled trial pools for Zepbound (SURMOUNT), Wegovy (STEP) and Ozempic (SUSTAIN). Note that tirzepatide’s rates at the highest 15 mg dose run roughly half of semaglutide’s 2.4 mg rate on the Wegovy label, despite the dual GIP/GLP-1 mechanism producing more first-dose gastric-emptying delay.[2][7][12][13]
- Wegovy 2.4 mg (FDA label pool)24.0 % reported constipationsemaglutide comparator
- Zepbound 5 mg (FDA label, SURMOUNT-1/-2 pool)17.0 % reported constipation
- Zepbound 10 mg (FDA label, SURMOUNT-1/-2 pool)14.0 % reported constipation
- Zepbound 15 mg (FDA label, SURMOUNT-1/-2 pool)11.0 % reported constipation
- Placebo (Wegovy label pool)11.0 % reported constipationobesity-trial background
- Placebo (Zepbound label pool)5.0 % reported constipation
- Ozempic 1 mg (FDA label pool, incl. SUSTAIN-1)3.1 % reported constipationdiabetes-dose semaglutide
Constipation management decisions should always be made with your prescribing clinician, particularly if you have chronic kidney disease, heart failure, or are taking multiple other medications. If you have any of the red flag symptoms listed above (no stool for 5+ days plus abdominal pain or vomiting, progressive distension, inability to pass gas), seek care promptly.
Further reading
- Top tirzepatide questions on Reddit, answered
- Top tirzepatide weight-loss studies (curated PubMed reading list)
- GLP-1 sick-day guide cheat sheet
Our reviews
Providers that offer tirzepatide
Telehealth providers we’ve reviewed. Each opens our full, independent review.
Featured partners
Partners · our scores never change
- Editorial score: 7.8. Read our review of EmbodyLow flat-rate compounded GLP-1 pricing at every doseFrom$129/mosale pricecompounded
- Editorial score: 7.8. Read our review of SnagRxCompounded semaglutide and tirzepatide at a flat lifetime priceFrom$149/mocompounded
- Editorial score: 7.7. Read our review of Live VitalLow-cost, physician-led compounded GLP-1 with peptide and hormone optionsFrom$239/moafter intro offercompounded
- Editorial score: 7.7. Read our review of TrimRxBest overall valueFrom$279/mostarting dosecompounded
- Editorial score: 7.5. Read our review of Luvo HealthCompounded and brand GLP-1s, oral tablets and microdosing on one public price listFrom$179/4 wksbilled per 4 weekscompounded
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
References
- 1.Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use — US Prescribing Information. Sections 5.2 Acute Pancreatitis, 5.3 Acute Kidney Injury, 5.7 Pulmonary Aspiration, and 6.1 Adverse Reactions. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- 2.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use — US Prescribing Information. Sections 5 Warnings and Precautions, 6.1 Adverse Reactions (SURMOUNT-1/-2/-3/-4 pooled). DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 3.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. PMID: 35658024.
- 4.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA; SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
- 5.Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, Sands SA, Schwab RJ, Dunn JP, Chakladar S, Bunck MC, Bednarik J; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. PMID: 38912654.
- 6.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185.
- 7.Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017. PMID: 28110911.
- 8.Urva S, Coskun T, Loghin C, Cui X, Beebe E, O’Farrell L, Briere DA, Benson C, Nauck MA, Haupt A. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020. PMID: 32519795.
- 9.Marathe CS, Rayner CK, Jones KL, Horowitz M. Glucagon-like peptides 1 and 2 in health and disease: a review. Peptides. 2013. PMID: 23523778.
- 10.Anderson JW, Baird P, Davis RH Jr, Ferreri S, Knudtson M, Koraym A, Waters V, Williams CL. Health benefits of dietary fiber. Nutr Rev. 2009. PMID: 19335713.
- 11.Mori S, Tomita T, Fujimura K, Asano H, Ogawa T, Yamasaki T, Kondo T, Kono T, Tozawa K, Oshima T, Fukui H, Kimura T, Watari J, Miwa H. A Randomized Double-blind Placebo-controlled Trial on the Effect of Magnesium Oxide in Patients With Chronic Constipation. J Neurogastroenterol Motil. 2019. PMID: 31587548.
- 12.Novo Nordisk. WEGOVY (semaglutide) injection, for subcutaneous use: US Prescribing Information. Section 6.1 Adverse Reactions, Table 3. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 13.Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use: US Prescribing Information. Section 6.1 Adverse Reactions, Table 1. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
Related research
Mounjaro Constipation: SURPASS-1 Rates, Mechanism & Evidence-Based Relief Protocol
Constipation is a recognized but lower-rate GI side effect on Mounjaro. SURPASS-1 reports ~6-7% on 15 mg vs. ~1-2% placebo over 40 weeks. Covers dual GIP+GLP-1 mechanism, diabetic-gastroparesis context, metformin interaction, fiber-fluid-magnesium relief, and ileus red flags.
13 min read
Tirzepatide Burping & Sulfur Burps: FDA Label Rates + Mechanism Evidence
Burping is a labeled side effect of tirzepatide: eructation in 4-5% on Zepbound 5-15 mg and 2.5-3.3% on Mounjaro. Delayed gastric emptying drives it; a rotten-egg smell comes from hydrogen sulfide made by gut bacteria. Diet changes, OTC relief and red flags.
14 min read
Zepbound Nausea: SURMOUNT-1 Rates, Mechanism, Timeline & Evidence-Based Relief Protocol
Nausea is the most common Zepbound side effect. The Zepbound label reports 28% on tirzepatide 15 mg vs 8% placebo over 72 weeks, lower than the 44% on the Wegovy label. Guide covers dual GIP+GLP-1 mechanism, titration timeline, relief protocol, pancreatitis red flags.
13 min read
Mounjaro and Constipation: Why It Happens & How to Get Relief (2026)
Constipation is a labeled, common side effect of Mounjaro (tirzepatide). Why it happens, prescriber-directed relief, red flags like ileus, and how it eases as your body adjusts.
7 min read
GLP-1s and Hemorrhoids: The Constipation Connection
GLP-1 hemorrhoids come from constipation and straining, not the drug itself. Evidence-based prevention, relief, and the bleeding red flags that need a doctor.
8 min read
Wegovy Bloating and Gas: Causes and Remedies
Why Wegovy (semaglutide 2.4 mg) causes bloating, gas, and belching — the delayed-gastric-emptying mechanism, when it's worst, the remedy stack, and red flags.
8 min read
Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
From $149/mo
From $209/mo
microdose, 2-month plan rate
HumeCare+
GLP-1 weight loss with real-time body-composition tracking to protect muscle
Read full review →From $299/mo